Market Cap (In JPY)
3.53 Billion
Revenue (In JPY)
194.16 Million
Net Income (In JPY)
-258.33 Million
Avg. Volume
158.69 Thousand
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 263.0-442.0
- PE
- -
- EPS
- -
- Beta Value
- 0.827
- ISIN
- JP3981100005
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Healthcare
- CEO
- Keisuke Furuta
- Employee Count
- -
- Website
- https://www.renascience.co.jp
- Ipo Date
- 2021-09-24
- Details
- Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
More Stocks
-
CMTVCommunity Bancorp
CMTV
-
3511
-
TCLCFTranscontinental Inc.
TCLCF
-
MLLUY
-
002811
-
012630HDC HOLDINGS CO.,Ltd
012630
-
CVG
-
9251AB&Company Co.,Ltd.
9251